Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $580.4M
Founded date: 2017
Investors 4
| Date | Name | Website |
| 13.07.2025 | Foresite C... | foresiteca... |
| 14.07.2025 | Terra Magn... | terramagnu... |
| - | F-Prime Ca... | fprimecapi... |
| 23.01.2024 | Qiming Ven... | qimingvc.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.06.2024 | - | $547.4M | - |
| 31.07.2022 | Series B | $33M | - |
Mentions in press and media 17
| Date | Title | Description |
| 10.01.2026 | 2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market | In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today’s blockbuster injections that could attract entirely new patient... |
| 11.12.2025 | Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly | Ahead of its Capital Markets Day Thursday, Zealand Pharma unveiled its “Metabolic Frontier 2030” strategy. The strategy comes as Zealand shares have dropped 29% year to date, with investors betting on the weight loss drug market to fragment... |
| 24.08.2025 | Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors | Some analysts say Eli Lilly’s daily obesity pill, if approved, could still be a viable competitor in the weight loss drug market despite late-stage trial data that disappointed investors. In the trial, orforglipron caused weight loss that m... |
| 07.08.2025 | Eli Lilly shares drop after obesity pill shows modest late-stage trial results | Eli Lilly said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial. They bring Eli Lilly’s pill, orforglipron, one step closer to potential... |
| 17.04.2025 | Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14% | Eli Lilly said its daily obesity pill met the company’s goals in the first of several closely watched late-stage trials. The pill helped Type 2 diabetes patients lower their blood sugar and body weight and showed safety on par with popular ... |
| 17.04.2025 | Lilly weight-loss pill works as well as Ozempic, shares surge | Lilly weight-loss pill works as well as Ozempic, shares surge By Deena Beasley and Manas MishraApril 17, 20254:02 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link The logo of Lilly is seen on a w... |
| 25.03.2025 | The Weight of Expectations: A Look at the Obesity Drug Market's Rollercoaster Ride | The obesity drug market is a battleground, where hopes soar and plummet with each trial result. Recent developments from Novo Nordisk and Eli Lilly illustrate this volatile landscape. Both companies are vying for dominance in a sector proje... |
| 24.03.2025 | Eli Lilly will soon release key data on its weight loss pill. Here’s why it could be a game-changer | Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The trial results are among the pharmaceutical industry’s most critical of the year, as... |
| 18.10.2024 | The Microbiome Revolution: Holobiome's $9 Million Leap Forward | In the world of health and wellness, the gut is the new frontier. Holobiome, a microbiome platform company, has just secured $9 million in a Seed funding round. This investment is not just a financial boost; it’s a signal that the microbiom... |
| 18.10.2024 | Consumer groups ask FTC to block Novo Holdings-Catalent deal | Boards, Policy & RegulationMergers & Acquisitions Regulatory Oversight Corporate Counsel Health Consumer groups ask FTC to block Novo Holdings-Catalent deal By Jody Godoy and Maggie FickOctober 17, 20249:55 PM UTCUpdated ago Text Sm... |
Show more